drugset / Trial / NCT00703482

A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes

NCT00703482

Phase 2 Completed 278 enrolled Solvay Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to study the effect of different combinations of fenofibrate and coenzyme Q10 on ventricular diastolic function in patients with Type II diabetes

Timeline

Start
2003-05
Primary completion
2004-09
Completion
2004-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Coenzyme Q10 Other / unclassified 100 mg
Subject Coenzyme Q10 Other / unclassified 200 mg
Subject Fenofibrate Small molecule 80 mg
Subject Fenofibrate Small molecule 160 mg

Indications

No indication recorded.